ReviewInternational journal of endocrinology2015
Osteoprotegerin in Cardiometabolic Disorders.
Review in International journal of endocrinology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 1 synthesis or guideline pooled it, 80 citations in OpenAlex.
- Pooled it
- Effect of active vitamin D treatment on development of type 2 diabetes: DPVD randomised controlled trial in Japanese population.BMJ (Clinical research ed.) · 2022Trial
- Reframing Heart Failure as a Multiorgan Network Disorder: Translational and Regenerative Perspectives in Veterinary Cardiology.Veterinary sciences · 2026Review
- Sex-biased plasma inflammatory protein profile in obesity.Scientific reports · 2026Article
- Juvenile Paget disease with unique compound heterozygous sequence variants in the TNFRSF11B gene.Orphanet journal of rare diseases · 2025Article
- Osteoprotegerin and its ligands RANKL and TRAIL in falciparum, vivax, and knowlesi malaria.iScience · 2025Article
- Osteoprotegerin as an Emerging Biomarker of Carotid Artery Stenosis? A Scoping Review with Meta-Analysis.Diagnostics (Basel, Switzerland) · 2025Review
- Article
- Identification of pyroptosis-associated genes with diagnostic value in calcific aortic valve disease.Frontiers in cardiovascular medicine · 2024Article
- Critical illness and bone metabolism: where are we now and what is next?European journal of medical research · 2022Review
- Association Between Serum Selenium Concentration and OPG/RANKL/RANK Axis in Patients with Arterial Hypertension.Cardiovascular toxicology · 2022Article
- Frailty in Aging and the Search for the Optimal Biomarker: A Review.Biomedicines · 2022Review
- Plasma proteins, cognitive decline, and 20-year risk of dementia in the Whitehall II and Atherosclerosis Risk in Communities studies.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2022Article
- Serum Osteoprotegerin Is an Independent Marker of Metabolic Complications in Non-DialysisDependent Chronic Kidney Disease Patients.Nutrients · 2021Observational
- Cardiac Adipose Tissue Contributes to Cardiac Repair: a Review.Stem cell reviews and reports · 2021Review
- Serum osteoprotegerin level in hemodialysis patients using low-flux reused dialyzer in relation to atherosclerosis.Journal of clinical laboratory analysis · 2021Article
- Association Between Factors Involved in Bone Remodeling (Osteoactivin and OPG) With Plasma Levels of Irisin and Meteorin-Like Protein in People With T2D and Obesity.Frontiers in endocrinology · 2021Article
- Early Endothelial Activation Precedes Glycocalyx Degradation and Microvascular Dysfunction in Experimentally Induced Plasmodium falciparum and Plasmodium vivax Infection.Infection and immunity · 2020Article
- Vascular Calcification-New Insights Into Its Mechanism.International journal of molecular sciences · 2020Review
- The role of osteoprotegerin in the development, progression and management of abdominal aortic aneurysms.Open medicine (Warsaw, Poland) · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
Abstract
Osteoprotegerin (OPG), a glycoprotein traditionally implicated in bone remodelling, has been recently related to cardiovascular disease (CVD). Human studies show a positive relationship between circulating OPG, vascular damage, and CVD, and as such OPG has emerged as a potential biomarker for CVD. This review focuses on the relationship between circulating OPG and different endocrine cardiometabolic alterations such as type 1 and 2 diabetes. The association of OPG with diabetic complications (neuropathy, nephropathy, or retinopathy) as well as with atherosclerosis, coronary artery calcification, morbidity, and mortality is pointed out. Moreover, OPG modulation by different treatments is also established. Besides, other associated diseases such as obesity, hypertension, and metabolic syndrome, which are known cardiovascular risk factors, are also considered.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.